Paris, September 25 . 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and Simon Lambden as Head of Medical Science.
Inotrem’s clinical study on Covid-19 was selected by the French government to be part of its €78 M action plan aimed at reinforcing the countries’ research capabilities for therapeutic solutions.
Intensive Care Medicine publishes the results of Inotrem’s study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.
Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced a €5M capital increase financed by Fountain Healthcare Partners, a leading Irish venture capital firm with offices in Dublin and New
January 20. 2020. Paris, France. Inotrem was chosen to join the French Tech 120. This program, launched by the President of the Republic and the Prime Minister in September 2019, is dedicated to support the development of fast growing startups. The French Tech Mission brings together some 50 French Tech
January 21. 2020. Paris, France. Inotrem has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This agreement consolidates existing ties between Roche Diagnostics and Inotrem who are jointly developing since 2017 an in vitro assay
March 24. 2020. Brussels, Belgium. Inotrem will attend the 40th International Symposium on Intensive Care & Emergency Medicine which stands as one of the largest meeting in its field, attracting more than 6200 participants. During the Symposium, Inotrem will present a poster showing for the first time the association between
February 27-28, 2020. Washington DC. Inotrem will attend the 3CT Workshop (Critical Care Clinical Trialists) that will take place at the French Embassy on February 27th and 28th 2020 in Washington DC. During the 2-days Symposium, Inotrem will present the design of its ASTONISH Phase IIb clinical trial for Nangibotide
January 13-16, 2020. San Francisco. Inotrem will participate to the annual J.P. Morgan Healthcare Conference. It is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
December 3, 2019. Nancy. Cecile Jouclas, Inotrem’s Administrative and Financial Officer, will participate to the Deeptech Tour organized by the BPI. Cecile will be a host at the workshop “What tools to finance your deeptech project?” that will take place on the Université de Lorraine’s campus. Throughout France, the Deeptech
Paris (France). November 21. 2019. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient
October 8-12 in Chania, Crete, Greece. Marc Derive, Co-founder and CSO of Inotrem, will present new preclinical data during the 18th ESS congress and 9th Congress of the IFSS, entitled “TREM-1 pharmacological inhibition by LR12/nangibotide improves survival and controls vascular leakage during experimental endotoxic shock in mice” in a session
28 September – 2 October 2019 in Berlin, Germany. European Society of Intensive Care Medicine’s (ESICM) annual congress attracts audiences of over 6,000 physicians, anesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. A diverse faculty of more than 300 international speakers
Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners
Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide development program for the treatment of septic shock. Nangibotide, which Phase IIb has just been
Paris (France). August 6. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for the ASTONISH trial (Phase IIb) where the safety, tolerance and efficacy of nangibotide (LR12),
July 9. 2019 in Paris. Jean-Jacques Garaud, CEO at Inotrem, will be a speaker at the Solebury Trout Summer Investor tour, hosted by Andera Partners in Paris.
June 24. & June 25. 2019 in Paris. Inotrem will attend this exclusive event organized by France Biotech which brings together French and European HealthTech leaders, large pharmaceutical companies and international investors in health innovation.
June 17. 2019 in Paris (La Défense). Dr. Margarita Salcedo Magguilli, CDP at Inotrem, will be speaking at the roundtable “New regulatory paths to innovation” during the 3rd Biotech Meeting Day (Les Rencontres de la Biotech) organized by Pharmaceutiques.
May 5. 2019. Discover the interview of Jean-Jacques Garaud, CEO of Inotrem, laying out Inotrem’s recent milestones and internationalization strategy in PharmaBoardRoom.
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices